
URGN
UroGen Pharma Ltd.
$19.45
+$0.21(+1.09%)
75
Overall
--
Value
75
Tech
--
Quality
Market Cap
$902.15M
Volume
1.29M
52W Range
$3.42 - $21.02
Target Price
$33.67
Order:
Income Statement
Metric | Trend | Chart | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||
Total Revenue | $8.2M | $1.1M | $18.0K | $11.8M | $48.0M | $64.4M | $82.7M | $90.4M | ||
Total Revenue | $8.2M | $1.1M | $18.0K | $11.8M | $48.0M | $64.4M | $82.7M | $90.4M | ||
COST OF GOODS SOLD | ||||||||||
Cost of Revenue | $-600.0K | $-1.8M | -- | $1.0M | $5.2M | $7.7M | $9.4M | $8.9M | ||
GROSS PROFIT | ||||||||||
Gross Profit | $7.6M | $-675.0K | $18.0K | $10.8M | $42.9M | $56.7M | $73.4M | $81.5M | ||
OPERATING EXPENSES | ||||||||||
Operating Expenses | $27.5M | $76.5M | $109.5M | $138.5M | $140.3M | $135.7M | $138.9M | $178.3M | ||
Research & Development | -- | $36.9M | $49.3M | $47.3M | $47.6M | $52.9M | $45.6M | $57.1M | ||
Research Expense | -- | $36.9M | $49.3M | $47.3M | $47.6M | $52.9M | $45.6M | $57.1M | ||
Selling, General & Administrative | $8.8M | $39.6M | $60.2M | $91.2M | $92.7M | $82.8M | $93.3M | $121.2M | ||
Selling & Marketing Expenses | -- | -- | $60.2M | $1.0M | -- | -- | -- | -- | ||
General & Administrative Expenses | $8.8M | $39.6M | $60.2M | $90.2M | $92.7M | $82.8M | $93.3M | $121.2M | ||
Salaries & Wages | $18.7M | $-30.6M | $-30.0M | -- | -- | -- | $9.3M | $13.1M | ||
Depreciation & Amortization | $-200.0K | $-400.0K | $-300.0K | $416.0K | $831.0K | $924.0K | $802.0K | $329.0K | ||
Depreciation & Amortization | $-200.0K | $-400.0K | $-300.0K | $416.0K | $831.0K | $924.0K | $802.0K | $329.0K | ||
Amortization | -- | -- | -- | -- | -- | -- | -- | $36.0K | ||
Other Operating Expenses | $-27.5M | $-76.5M | $-109.5M | $-2.7M | $5.2M | -- | -- | -- | ||
OPERATING INCOME | ||||||||||
Operating income | $-19.9M | $-77.2M | $-109.5M | $-126.7M | $-92.3M | $-79.0M | $-65.5M | $-96.8M | ||
EBITDA | $-19.8M | $-75.1M | $-104.4M | $-124.7M | $-107.6M | $-97.8M | $-80.9M | $-111.6M | ||
NON-OPERATING ITEMS | ||||||||||
Interest Expense (Non-Operating) | -- | -- | -- | -- | -- | $8.4M | $14.7M | $12.5M | ||
Interest Income Operating | $-31.0K | -- | -- | -- | -- | -- | -- | -- | ||
Intinc | -- | $1.6M | $4.6M | $2.0M | $212.0K | $1.0M | $3.5M | $8.9M | ||
Net Non-Operating Interest Income/Expense | -- | $1.6M | $4.6M | $2.0M | $212.0K | $7.5M | $-14.7M | $-12.5M | ||
Gain on Sale of Securities | -- | $-100.0K | -- | -- | -- | -- | -- | -- | ||
Other Income/Expense | $-168.0K | $224.0K | $-4.3M | -- | $153.0K | $-21.5M | $-838.0K | $229.0K | ||
Other Special Charges | $168.0K | $-124.0K | $4.3M | -- | $-153.0K | $72.0K | $838.0K | $-229.0K | ||
SPECIAL ITEMS | ||||||||||
Special Income Charges | -- | -- | -- | $-1.0M | -- | -- | -- | -- | ||
Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | ||
PRE-TAX INCOME | ||||||||||
EBIT | $-20.0M | $-75.5M | $-105.1M | $-126.7M | $-109.4M | $-99.6M | $-83.6M | $-111.5M | ||
Pre-Tax Income | $-20.0M | $-75.5M | $-105.1M | $-125.1M | $-109.4M | $-108.0M | $-98.3M | $-124.0M | ||
INCOME TAX | ||||||||||
Tax Provision | $19.0K | $125.0K | $257.0K | $3.4M | $1.4M | $1.8M | $3.9M | $2.8M | ||
NET INCOME | ||||||||||
Net Income | $-20.0M | $-75.7M | $-105.1M | $-128.5M | $-110.8M | $-109.8M | $-102.2M | $-126.9M | ||
Net Income (Continuing Operations) | $-20.0M | $-75.7M | $-105.1M | $-128.5M | $-110.8M | $-109.8M | $-102.2M | $-126.9M | ||
Net Income (Discontinued Operations) | $-20.0M | $-75.7M | $-105.1M | $-128.5M | $-110.8M | $-109.8M | $-102.2M | $-126.9M | ||
Net Income (Common Stockholders) | $-20.0M | $-75.7M | $-105.1M | $-128.5M | $-110.8M | $-109.8M | $-102.2M | $-126.9M | ||
Normalized Income | -- | -- | -- | -- | -- | -- | -- | $-122.8M | ||
TOTALS | ||||||||||
Total Expenses | $26.9M | $74.7M | $109.5M | $139.5M | $145.5M | $143.4M | $148.2M | $187.2M | ||
SHARE & EPS DATA | ||||||||||
Average Shares Outstanding | $9.7M | $15.8M | $20.5M | $21.8M | $22.3M | $22.8M | $28.8M | $42.9M | ||
Average Shares Outstanding (Diluted) | $9.3M | $15.8M | $20.5M | $21.8M | $22.3M | $22.8M | $28.8M | $42.9M | ||
Shares Outstanding | $13.8M | $20.5M | $21.2M | $22.3M | $22.7M | $23.4M | $34.1M | $46.1M | ||
Basic EPS | -- | -- | -- | $-5.9 | $-4.96 | $-4.81 | $-3.55 | $-2.96 | ||
Basic EPS (Continuing Operations) | -- | -- | -- | $-5.9 | $-4.96 | $-4.81 | $-3.55 | $-2.96 | ||
Diluted EPS | $-2.14 | $-4.8 | $-5.12 | $-5.9 | $-4.96 | $-4.81 | $-3.55 | $-2.96 | ||
Diluted EPS (Continuing Operations) | -- | -- | $-5.12 | -- | -- | -- | -- | -- | ||
OTHER METRICS | ||||||||||
Gain On Sale Of P P E | -- | $1.6M | -- | -- | -- | -- | -- | -- | ||
Insurance And Claims | -- | -- | -- | -- | $5.2M | -- | -- | -- | ||
Other Gand A | $8.8M | $39.6M | $60.2M | $90.2M | $92.7M | $82.8M | $93.3M | $121.2M | ||
Otherunder Preferred Stock Dividend | $-825.0K | -- | -- | -- | -- | -- | -- | -- | ||
Preferred Stock Dividends | $-825.0K | -- | -- | -- | -- | -- | -- | -- | ||
Rent And Landing Fees | $8.8M | $39.6M | -- | -- | -- | -- | -- | -- | ||
Selling Expense | -- | -- | $60.2M | -- | -- | -- | -- | -- | ||
Write Down | -- | -- | -- | $1.0M | -- | -- | -- | -- |
Financial data is updated quarterly and may not reflect the most recent earnings.
A | B | C | D | |
---|---|---|---|---|
1 | Symbol | Price | Change | Vol |
2 | URGN | $19.45 | +1.1% | 1.29M |
3 | ||||
4 | ||||
5 | ||||
6 |